Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
Key facts
- Who runs it
- Istituto Giannina Gaslini
- Where
- Belgium, Czechia, Denmark, Italy, Lithuania, Portugal, and Spain24 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 166 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Treatment medication withdrawal strategy
- Record updated
- 1 October 2024
Who can take part
- Age
- 2 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- - Children with a diagnosis of JIA according to the ILAR classification criteria
- JIA patients who satisfy criteria for inactive disease for a minimum of 6 continuous months while still taking medication
- Patients who have been treated with cs/b/bs/ts DMARDs according to the label indication
- Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and/or patients, as appropriate
- Duly executed, written, informed consent obtained from the patient's parents/legal guardian
- Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial. If sexually active, they must have no intention of conceiving while on treatment with antirheumatic drugs
Who cannot take part
- Patients who received glucocorticoid treatment 3 months prior to baseline visit
- Patients who had previously unsuccessfully attempted tapering cs/b/bs/tsDMARDs
- Prior or current history of other significant concomitant illness(es) that, according to the Investigator's judgment, would adversely affect the patient's participation in the study
- Patients with severe disease-related ocular damage and who need systemic treatment for uveitis
- Any other medical condition or laboratory examination which in the opinion of the caring physician should exclude the patient from participation to the study
- - Patients with systemic JIA according to ILAR criteria
- Patients with undifferentiated arthritis according to ILAR criteria
- Patients with severe damage as per caring physician measured
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 18 years old?
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Biologic therapies made clinical remission an achievable goal for most juvenile idiopathic arthritis (JIA) patients. Nevertheless, antirheumatic drugs have side effects and are costly. Currently, no guidelines exist for withdrawing drugs in JIA patients with clinical inactive disease (CID). Relapses following the withdrawal of antirheumatic drugs are common. To establish an optimal timeline for treatment discontinuation is a major unmet need in pediatric rheumatology.
Read full original descriptionShow less
It is hypothesized that biomarkers-guided early withdrawal of antirheumatic drugs in patients achieving clinical, imaging and biological remission is safe and more effective compared to the standard practice of maintenance of stable treatment over 12 months.
The 2 groups in the trial
- Biomarker-guided drug withdrawalTreatment being tested
Patients with inactive disease, absence of sublinical synovitis at the joint level and normal S100A8/9 and hs-CRP leves will be randomly assigned to either an early biomarker-guided drug withdrawal protocol (interventional arm) or continuation of ongoing therapy at unchanged dose for an additional 6 months and then gradual tapering (control arm). Patients will be evaluated at baseline, then every 3 months if still on treatment and every 6 months after drug withdrawal. At each timepoint the following procedures will be performed: joint assessment, Physician's Global Assessment of Overall Disease Activity, JAMAR, Uveitis assessment (in ANA positive patients), Hematology, chemistry, CRP, ESR, urine analysis according to drug specific schedule and Good Clinical Practice (GCP). Drug Adverse Events will be collected (MedDRA). MSUS and serum biomarkers quantification (S100A8/9, hs-CRP) will be repeated every 3 months until month 18 in patients with subclinical synovitis and pathologic values
Treatment: Treatment medication withdrawal strategy
- Gradual taperingNo study treatment, for comparison
The control arm will continue ongoing therapy at unchanged dose for an additional 6 months and then will gradually taper the therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission: a Randomized Clinical Trial Comparing Early Versus Late Drug Withdrawal Combining Imaging and Multi-Omics
- Fit questions
- Built from NCT06618937, who can take part
- Record updated
- 1 October 2024